Page 55 - NobleCon21

BioLargo, Inc.

SELECTED FINANCIAL ITEMS BLGO
(in millions of USD)
CQ4 '24 CQ1 '25 CQ2 '25 CQ3 '25 LTM
Income Statement Key Items
Total Revenue 3.66 3.27 2.78 1.10 10.81
Gross Profit 1.75 1.49 1.42 0.37 5.03
Gross Margin 48% 46% 51% 34% 47%
EBIT (1.62) (1.86) (1.80) (7.18) (12.46)
EBIT Margin -44% -57% -65% -651% -115%
Net Income to Common Shareholders (1.73) (1.92) (1.88) (7.24) (12.78)
Net Margin -47% -59% -68% -657% -118%

Balance Sheet Key Items
Total Assets 10.51 10.51 12.50 9.13 9.13
Cash & Short Term Investments 3.55 2.56 3.47 4.55 4.55
% of Assets 34% 24% 28% 50% 50%
Current Assets -Total 7.14 7.22 9.19 5.78 5.78
% of Assets 68% 69% 74% 63% 63%
Total Liabilities 4.46 5.42 6.44 5.92 5.92
% of Assets 42% 52% 52% 65% 65%
Current Liabilities - Total 2.65 3.37 4.08 3.45 3.45
% of Assets 25% 32% 33% 38% 38%
Long Term Debt 0.53 0.81 1.17 1.20 1.20
% of Assets 5% 8% 9% 13% 13%
Total Equity 6.06 5.09 6.06 3.22 3.22
% of Assets 58% 48% 48% 35% 35%

Cash Flow Statement Key Items
Net Cash Flow - Operating Activities (1.92) (1.83) (2.12) (2.76) (8.62)
Net Cash Flow - Investing (0.06) NA 0.19 0.26 0.39
Net Cash Flow - Financing 1.59 0.87 2.83 3.57 8.86

Source: Capital IQ

PRICE / VOLUME

Source: Channelchek/QuoteMedia

Noble Capital Markets' Twenty-First Annual Emerging Growth Equity Conference